The global self-injections market is experiencing robust growth, driven by the rising prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis, which necessitate long-term and convenient treatment options. The increasing demand for patient-centric healthcare solutions has led to the development of user-friendly self-injection devices, such as prefilled syringes, auto-injectors, and pen injectors, that enhance patient compliance and reduce dependency on healthcare professionals. Technological advancements, including digital monitoring features and smart injectors, are further propelling market expansion. In addition, the growing adoption of biologics and biosimilars, which often require self-administration, is significantly contributing to market growth. Key players, such as Novo Nordisk A/S, AbbVie Inc., and Amgen Inc., continue to innovate in this space, introducing new formulations and devices that improve ease of use and patient outcomes.
Global Self-Injections Market size was valued at USD 50.04 billion in 2024 and is projected to reach USD 107.07 billion by 2032, with a CAGR of 9.98% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-self-injections-market
Below are the Top Self-Injections Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Novo Nordisk A/S
|
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, with a strong portfolio of self-injection devices like insulin pens and GLP-1 receptor agonists. The company’s focus on innovation and patient-centric solutions has positioned it as a leader in the self-injection market, particularly for diabetes management. Its advanced pen devices, such as FlexTouch and FlexPen, enhance ease of use, contributing to widespread adoption among patients worldwide.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2024, Evotec shares jumped 6% after announcing a technology development partnership with Novo Nordisk centered on cell therapy. The collaboration involves funding for development activities in Germany and Italy, along with upfront payments, potential milestone achievements, and royalty incentives. Dr. Cord Dohrmann, Evotec's Chief Scientific Officer, expressed optimism about creating innovative stem cell-based therapies through this partnership.
|
|
2.
|
AbbVie Inc.
|
AbbVie Inc. is a biopharmaceutical company known for its leading autoimmune therapy, Humira®, one of the world’s top-selling self-injection biologics for conditions like rheumatoid arthritis and psoriasis. The company continues to expand its self-injection offerings with advanced formulations and delivery mechanisms that improve patient adherence and convenience, reinforcing its position in the global self-injections market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2024, AbbVie introduced the HUMIRA Auto-Injector Pen, designed to simplify the self-injection process for patients. The ergonomic design accommodates a wide range of hand sizes, including those with reduced grip strength or dexterity, aiming to reduce the burden on patients performing self-injections.
|
|
3.
|
Sanofi
|
Sanofi offers a diverse range of self-injection solutions, particularly in diabetes care and immunology. Its insulin pens, such as SoloStar, and biologic therapies like Dupixent for atopic dermatitis have gained strong market traction. Sanofi’s commitment to patient-friendly delivery systems and expanding biologics portfolio contributes to its strong presence in the self-injections market globally.
|
|
Americas, Middle East, Asia-Pacific, and Europe
|
In July 2024, Biogen has acquired Human Immunology Biosciences (HI-Bio), enhancing its immunology pipeline with felzartamab, a promising therapeutic candidate. The acquisition will advance felzartamab into Phase 3 trials for various indications. Positive interim results have been reported in Phase 2 studies for IgA nephropathy and antibody-mediated rejection.
|
|
4.
|
Amgen Inc.
|
Amgen Inc. is a biotechnology leader with a robust portfolio of self-injection biologics for oncology, nephrology, and autoimmune disorders. Products like Enbrel® for rheumatoid arthritis and Repatha® for cholesterol management highlight Amgen’s focus on innovative delivery systems that improve patient self-administration experiences. The company’s emphasis on biosimilars and biologic therapies continues to drive growth in the self-injection segment.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2018, Amgen launched the Aimovig SureClick Autoinjector, enabling patients to self-administer Aimovig (erenumab-aooe) for migraine prevention. The prefilled autoinjector is designed for monthly use, providing greater control over treatment regimens.
|
|
5.
|
Johnson & Johnson Private Limited
|
Johnson & Johnson, through its Janssen Pharmaceutical Companies, offers a variety of self-injection therapies targeting autoimmune diseases and oncology. With products like Stelara® for Crohn's disease and psoriasis, the company leverages its strong R&D capabilities to develop patient-friendly self-injection solutions. Johnson & Johnson’s global reach and commitment to improving patient outcomes reinforce its competitive position in the self-injections market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2024, Tremfya (guselkumab) was FDA-approved for adults with moderately to severely active ulcerative colitis, in addition to its approvals for plaque psoriasis and psoriatic arthritis. It is the first dual-acting interleukin-23 inhibitor for this condition, showing significant remission rates in the QUASAR study. Administered as a 200 mg intravenous induction dose, it follows with subcutaneous maintenance doses of 100 mg every 8 weeks or 200 mg every 4 weeks. This approval highlights Johnson & Johnson's commitment to advancing treatments for inflammatory bowel disease.
|
Conclusion
The global self-injections market is poised for sustained growth, fueled by the increasing prevalence of chronic diseases and the rising demand for convenient, patient-friendly treatment options. Technological advancements in self-injection devices, coupled with the growing adoption of biologics and biosimilars, are key drivers propelling market expansion. While challenges such as needle phobia and high device costs may pose barriers, ongoing innovations by leading companies like Novo Nordisk A/S, AbbVie Inc., and Amgen Inc. are addressing these concerns. With supportive healthcare initiatives and increased patient awareness, the market is expected to continue its upward trajectory, offering improved healthcare outcomes and greater autonomy for patients worldwide.
